[1] AGBAJE J O, ADISA A O, PETROVA M I, et al. Biological profile of ameloblastoma and its location in the jaw in 1246 Nigerians[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2018,126(5): 424-431.
[2] ALMEIDA RDE A, ANDRADE E S, BARBALHO J C,et al. Recurrence rate following treatment for primary multicystic ameloblastoma: systematic review and meta-analysis[J]. Int J Oral Maxillofac Surg, 2016,45(3): 359-367.
[3] EVANGELOU Z, ZARACHI A, DUMOLLARD J M, et al. Maxillary ameloblastoma: a review with clinical, histological and prognostic data of a rare tumor[J]. In Vivo, 2020,34(5): 2249-2258.
[4] RICARD A S, MAJOUFRE-LEFEBVRE C, SIBERCHICOT F, et al. A multirecurrent ameloblastoma metastatic to the lung[J]. Rev Stomatol Chir Maxillofac, 2010,111(2): 98-100.
[5] GOLUBOVIĆ M, PETROVIĆ M, JELOVAC D B,et al. Malignant ameloblastoma metastasis to the neck-radiological and pathohistological dilemma[J]. Vojnosanit Pregl, 2012,69(5): 444-448.
[6] BROWN N A, BETZ B L. Ameloblastoma: a review of recent molecular pathogenetic discoveries[J].Biomark Cancer, 2015,7(Suppl 2):19-24.
[7] DUTRA S N, PIRES F R, ARMADA L,et al. Immunoexpression of Wnt/beta-catenin signaling pathway proteins in ameloblastoma and calcifying cystic odontogenic tumor[J]. J Clin Exp Dent, 2017,9(1): e136-e140.
[8] EFFIOM O A, OGUNDANA O M, AKINSHIPO A O,et al. Ameloblastoma: current etiopathological concepts and management[J]. Oral Dis, 2018,24(3): 307-316.
[9] YOU Z, LIU S P, DU J,et al. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: a review[J]. J Oral Pathol Med, 2019,48(3): 201-205.
[10] GüLTEKIN S E, AZIZ R, HEYDT C, et al. The landscape of genetic alterations in ameloblastomas relates to clinical features[J]. Virchows Arch, 2018, 472(5):807-814.
[11] FUCHIGAMI T, ONO Y, KISHIDA S, et al. Molecular biological findings of ameloblastoma[J]. Jpn Dent Sci Rev, 2021,57: 27-32.
[12] ZHAO Z, BO Z, GONG W,et al. Inhibitor of differentiation 1(Id1) in cancer and cancer therapy[J]. Int J Med Sci, 2020,17(8):995-1005.
[13] COSTA S, PEREIRA N B, PEREIRA K,et al. DNA methylation pattern of apoptosis-related genes in ameloblastoma[J]. Oral Dis, 2017,23(6):779-783.
[14] MENDENHALL W M, WERNING J W, FERNANDES R, et al. Ameloblastoma[J]. Am J Clin Oncol, 2007, 30(6):645-648.
[15] FADEN D L, ALGAZI A. Durable treatment of ameloblastoma with single agent BRAFi Re: Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma[J]. J Natl Cancer Inst, 2017, 109(1): djw190.
[16] MURRAY V, HARDIE M E, GAUTAM S D. Comparison of different methods to determine the DNA sequence preference of ionising radiation-induced DNA damage[J]. Genes(Basel), 2019, 11(1):8.
[17] JAROSZ-BIEJ M, SMOLARCZYK R, CICHOń T, et al. Tumor microenvironment as a "game changer" in cancer radiotherapy[J]. Int J Mol Sci, 2019, 20(13):3212.
[18] CHEHAL A, LOBO R, NAIM A,et al. Ameloblastoma of the maxillary sinus treated with radiation therapy[J]. Pan Afr Med J, 2017,26:169.
[19] KENNEDY W R, WERNING J W, KAYE F J, et al. Treatment of ameloblastoma and ameloblastic carcinoma with radiotherapy[J]. Eur Arch Otorhinolaryngol, 2016, 273(10):3293-3297.
[20] PETROVIC I D, MIGLIACCI J, GANLY I, et al. Ameloblastomas of the mandible and maxilla[J].Ear Nose Throat J,2018,97(7):E26-E32.
[21] LIU J Y, MAN Q W, MA Y Q, et al. I(125) brachytherapy guided by individual three-dimensional printed plates for recurrent ameloblastoma of the skull base[J]. Br J Oral Maxillofac Surg, 2017, 55(7):e38-e40.
[22] YANG R N, WANG X S, REN J,et al. Mandible ameloblastoma with lung metastasis: a rare case report[J]. Int J Clin Exp Pathol, 2015,8(6): 6793-6799.
[23] LI D, XU S, SUN M,et al. MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: a case report[J]. Medicine:Baltimore, 2019,98(25): e15873. |
